• Users Online: 219
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Contacts Login 

    Article Cited by others


Wharton’s jelly derived allogeneic mesenchymal stromal cells for treatment of type 1 diabetes: Study protocol for a double-blinded, randomized, parallel, placebo-controlled trial

Carlsson Per-Ola, Svahn Mathias G

Year : 2018| Volume: 3| Issue : 2 | Page no: 32-37

   This article has been cited by
1 Wharton’s Jelly MSCs: Potential Weapon to Sharpen for Our Battle against DM
Dina H. Kassem,Mohamed M. Kamal
Trends in Endocrinology & Metabolism. 2020;
[Pubmed]  [Google Scholar] [DOI]
2 Therapeutic Potential of Wharton’s Jelly Mesenchymal Stem Cells for Diabetes: Achievements and Challenges
Mohamed M. Kamal,Dina H. Kassem
Frontiers in Cell and Developmental Biology. 2020; 8
[Pubmed]  [Google Scholar] [DOI]
3 Strategy for the Generation of Engineered Bone Constructs Based on Umbilical Cord Mesenchymal Stromal Cells Expanded with Human Platelet Lysate
Ingrid Silva-Cote,Mónica Cruz-Barrera,Mariana Cañas-Arboleda,Luz Correa-Araujo,Leidi Méndez,Joanna Jagielska,Bernardo Camacho,Gustavo Salguero
Stem Cells International. 2019; 2019: 1
[Pubmed]  [Google Scholar] [DOI]


Read this article